Phathom Pharmaceuticals (PHAT)

• Market cap: $975M
• 1 day: -3.47%
• 5 days: 5.98%
• 1 month: 5.89%
• 3 months: -4.3%
• 6 months: -7.7%
• Year to date: -22.15%
• 1 year: 409.58%
• 5 years: -65.02%
• 10 years: -50.28%
• Sector: Healthcare
• Industry: Biotechnology

About: Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Employees: 371